Dr Kimberly Blackwell - Duke University Medical Centre, USA
The typical presentation and course of receptor positive early breast cancer. The significance of positive receptors, whether oestrogen, progesterone or Her2neu. The comparative advantages of tamoxifen and the latest aromatase. Ongoing trials which are open to recruitment. Recent evidence for changes in personalised management of hormone sensitive early breast cancer.